Yibai Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 301 million yuan, a year-on-year decrease of 33.73%; net loss of 709.127 million yuan. The first three quarters of 2026 achieved operating income of 990 million yuan, a year-on-year decrease of 31.57%; net loss of 151 million yuan, after deducting non-net loss of 163 million yuan. The changes in performance were mainly due to a decline in drug sales, a decline in revenue and an increase in losses. On July 10, 2026, the company completed the cancellation of 7,533,500 repurchased shares, accounting for 0.95% of the total share capital before cancellation. The total share capital was changed to 784 million shares, and the registration of industrial and commercial changes was completed on August 24.

Yibai Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 301 million yuan, a year-on-year decrease of 33.73%; net loss of 709.127 million yuan. The first three quarters of 2026 achieved operating income of 990 million yuan, a year-on-year decrease of 31.57%; net loss of 151 million yuan, after deducting non-net loss of 163 million yuan. The changes in performance were mainly due to a decline in drug sales, a decline in revenue and an increase in losses. On July 10, 2026, the company completed the cancellation of 7,533,500 repurchased shares, accounting for 0.95% of the total share capital before cancellation. The total share capital was changed to 784 million shares, and the registration of industrial and commercial changes was completed on August 24.